| Literature DB >> 30464754 |
Carolina Camona1, Kevin B Wilkins1, Justin Drogos1, Jane E Sullivan1, Julius P A Dewald1,2,3, Jun Yao1.
Abstract
Purpose: In this study, we explored whether improved hand function is possible in poststroke chronic hemiparetic individuals with severe upper limb motor impairments when they participate in device-aided task-specific practice. Subjects: Eight participants suffering from chronic stroke (>1-year poststroke, mean: 11.2 years) with severely impaired upper extremity movement (Upper Extremity Subscale of the Fugl-Meyer Motor Assessment (UEFMA) score between 10 and 24) participated in this study.Entities:
Keywords: functional electric stimulation (FES); hand function; rehabilitation; stroke; task-practice; upper extremities
Year: 2018 PMID: 30464754 PMCID: PMC6234834 DOI: 10.3389/fneur.2018.00923
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Baseline characteristics.
| Age in years: mean (SD) | 63.5 (4) |
| Years since Onset: mean (median, SD) | 11.2 (9, 6.7) |
| Sex | |
| Female | 2 |
| Male | 6 |
| Side of Hemiparesis | |
| Right | 6 |
| Left | 2 |
| UE FMA Range (median, IQR) | 10-24 (19.5, 11.5) |
| Chedoke-MacMaster-Hand: median (IQR) | 3 (0.5) |
| Concordance | |
| Concordant | 4 |
| Discordant | 4 |
| Sensory Impairment, number of subjects /8 | |
| SWMT | 5/8 |
| NSA Stereognosis | 7/8 |
Concordant, The paretic limb is the dominant limb; Discordant, The paretic limb is the non-dominant limb; UEFM, Upper Extremity Fugl-Meyer Assessment (Max score 66); IQR, Interquartile range; SWMT, Cutaneous Sensory Touch Threshold using Semmes-Weinstein Monofilaments (normal detection threshold: 2.83 filament, 0.05 grams) NSA Stereognosis Sensory Impairment ≤ 19.
Figure 1Rein-Hand device and the experimental set up. FES parameters: Amplitude sufficient for maximal hand opening without discomfort, biphasic waveform, frequency 50 Hz ± 20%, and 300 μs pulse width, and duration time 3 s. Adapted from Wilkins et al. (27).
Outcomes at Baseline, Post and 3-Month Follow up.
| Activity | BBT | 0 (0.75) | 2 (5) | 0 (3) | 10.38 ( |
| Motor Impairment | PROM | 20.67 (25) | 30.83 (40) | 22.50 (37.5) | 12.45 ( |
| AROM | 0 (0) | 5 (14) | 4.50 (4) | 11.31 ( | |
| CMSA-H | 3(0.75) | 3 (0) | 3 (0) | 3 ( | |
| Grip Ratio: P/NP | 0.13 (0.36) | 0.14 (0.43) | 0.16 (0.36) | 4.71 ( | |
| UEFMA | 19.5 (11.5) | 19 (11) | 19 (11.5) | 4.33 ( | |
| Sensory Impairment | NSA | 15.5 (6) | 18 (4) | 19 (8) | 6.42 ( |
| SWMT | 2.83 (1.31) | 2.83 (1.31) | 2.83 (0) | 2.66 ( | |
Values are the median and interquartile range in parenthesis for Pre, Post and Follow up session. Results Chi-Square and (P value).
BBT, Box and Blocks Test; PROM, Passive Range of Motion; AROM, Active Range of Motion; CMSA-H, Chedoke-McMaster Stage of Hand section; P/NP, Paretic/Non Paretic; UEFM, Upper Extremity Fugl-Meyer; NSA, Nottingham-Stereognosis; SWMT, Cutaneous Sensory Touch Threshold using Semmes-Weinstein (SW) monofilament testing.
Significant p < 0.05.
| S1 | 2 | 3 | 3 | 0.24 | 0.3 | 0.3 | 33.33 | 58.33 | 33.33 | −20 | 11 | 3.5 | 23 | 23 | 23 |
| S2 | 3 | 3 | 3 | 0.15 | 0.2 | 0.2 | 3.33 | 8.33 | −20.67 | 0 | 5 | 5 | 11 | 12 | 11 |
| S3 | 2 | 3 | 2 | 0.09 | 0.1 | 0.0 | 10.50 | 19 | 31.67 | 0 | 0 | 0 | 17 | 17 | 13 |
| S4 | 3 | 3 | 3 | 0.10 | 0.1 | 0.1 | 23.33 | 40.00 | 28.33 | 0 | 17.5 | 5 | 10 | 11 | 11 |
| S5 | 3 | 3 | 3 | 0.60 | 0.7 | 0.3 | 55.00 | 55.67 | 55.00 | 0 | 2.5 | 3 | 24 | 24 | 23 |
| S6 | 3 | 3 | 3 | 0.07 | 0.1 | 0.1 | 20.00 | 33.33 | 19.33 | 0 | 1.5 | 0 | 13 | 13 | 12 |
| S7 | 3 | 3 | 3 | 0.11 | 0.1 | 0.1 | −13.33 | −5.00 | −9.00 | 0 | 5 | 4 | 24 | 24 | 24 |
| S8 | 4 | 4 | 4 | 0.52 | 0.6 | 0.6 | 13.33 | 28.33 | 8.33 | 38.5 | 55 | 52.5 | 22 | 21 | 21 |
| S1 | 0 | 6 | 4 | 19 | 20 | 19 | 20 | 19 | 20 | 2.83 | 3.61 | 2.83 |
| S2 | 1 | 3 | 0 | 18 | 19 | 18 | 20 | 19 | 20 | 2.83 | 2.83 | 2.83 |
| S3 | 0 | 1 | 0 | 20 | 20 | 20 | 20 | 20 | 20 | 2.83 | 2.83 | 2.83 |
| S4 | 0 | 1 | 0 | 14 | 19 | 18 | 20 | 20 | 20 | 2.83 | 2.83 | 2.83 |
| S5 | 0 | 0 | 0 | 13 | 20 | 16 | 19 | 16 | 19 | 2.83 | 2.83 | 2.83 |
| S6 | 0 | 0 | 0 | 17 | 20 | 20 | 20 | 20 | 20 | 3.61 | 2.83 | 2.83 |
| S7 | 0 | 3 | 0 | 12 | 20 | 15 | 20 | 12 | 20 | 4.31 | 4.31 | 4.31 |
| S8 | 11 | 13 | 8 | 0 | 20 | 2 | 20 | 0 | 20 | 6.65 | 6.65 | 6.65 |
S, Subject; Pre, Pre assessment; Post, Post assessment; 3M, 3 Month-follow up; P, Paretic arm; NP, Non paretic arm; PROM, Passive Range of Motion; AROM, Active Range of Motion; P/NP, Paretic/Non Paretic ratio; W-II-V, Wrist; 2nd and 5th Metacarpophalangeal joints; II-V, 2nd and 5th Metacarpophalangeal joints; AVE, Average; CMSA-H, Chedoke-McMaster Stage of Hand section; UEFM, Upper Extremity Fugl-Meyer Assessment (Max score 66); SWMT, Cutaneous Sensory Touch Threshold using Semmes-Weinstein Monofilaments (normal detection threshold, 2.83 filament; 0.05 grams); NSA, Nottingham-Stereognosis (Sensory Impairment ≤ 19); BBT, Box and Blocks Test.